Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 7/20 | 0.40 |
| ▸ | NTSR2 | O95665 | 5/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30512014 | 0.87 | XIAP (0.45) | XIAPNTSR1NTSR2SORT1 | |
| SCHEMBL31518676 | 0.86 | XIAP (0.49) | XIAPOPRD1NTSR1NTSR2SORT1 | |
| SCHEMBL29411290 | 0.82 | DPP4 (0.43) | XIAPNTSR1NTSR2 | |
| SCHEMBL29567377 | 0.81 | XIAP (0.47) | XIAPNTSR1 | |
| SCHEMBL29565370 | 0.81 | XIAP (0.50) | XIAP | |
| SCHEMBL29565348 | 0.81 | XIAP (0.41) | XIAP | |
| SCHEMBL30631601 | 0.81 | DPP4 (0.46) | XIAPNTSR1NTSR2 | |
| SCHEMBL30631602 | 0.81 | DPP4 (0.46) | XIAPNTSR1NTSR2 | |
| SCHEMBL29692652 | 0.80 | XIAP (0.50) | XIAP | |
| SCHEMBL30799477 | 0.80 | CALCRL (0.48) | XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122091012-A | Multi-target generation system and method of implantable degradable hydrogel slow-release carrier | — | 2026-05-26 | — | — | CN | claimed |
| US-20260007724-A1 | METHODS AND COMPOSITIONS FOR IMPROVING WOUND HEALING | US HEALTH (US) | 2026-01-08 | — | — | US | claimed |
| EP-4551259-A1 | METHODS AND COMPOSITIONS FOR IMPROVING WOUND HEALING | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-05-14 | — | — | EP | claimed |
| CN-119816333-A | Methods and compositions for improving wound healing | 美国卫生与公众服务部 | 2025-04-11 | — | — | CN | claimed |
| WO-2024011235-A1 | METHODS AND COMPOSITIONS FOR IMPROVING WOUND HEALING | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-01-11 | — | — | WO | claimed |
| CN-113774016-B | Oocyte in-vitro maturation 3D culture system | 中国医科大学附属盛京医院 | 2023-10-20 | — | — | CN | claimed |
| EP-4067370-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF PEPTIDES AND PEPTIDE RELATED COMPOUNDS | Yu, Chongxi (US) | 2022-10-05 | — | — | EP | claimed |
| CN-122091012-A | Multi-target generation system and method of implantable degradable hydrogel slow-release carrier | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4725962-A1 | PROCESS AND DEVICE FOR CULTIVATION OF IPSC | Gottfried Wilhelm Leibniz Universität Hannover (DE) | 2026-04-15 | — | — | EP | disclosed |
| EP-3980085-B1 | COMPOSITIONS AND METHODS OF USING SAME FOR TISSUE REGENERATION | UNIV RAMOT (IL) | 2026-03-11 | — | — | EP | disclosed |
| US-20260007724-A1 | METHODS AND COMPOSITIONS FOR IMPROVING WOUND HEALING | US HEALTH (US) | 2026-01-08 | — | — | US | disclosed |
| EP-3247328-B1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | GENEVANT SCIENCES GMBH (CH) | 2026-01-07 | — | — | EP | disclosed |
| US-20250296912-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | Illudent, Inc. (US) | 2025-09-25 | — | — | US | disclosed |
| EP-3978028-A1 | NEW COMBINATIONS OF BORON COMPOUNDS AND ADJUVANTS FOR THE TREATMENT OF PATHOPHYSIOLOGICAL CONDITIONS AND MUSCLE REGENERATION | Consorcio Centro de Investigación Biomédica en Red M.P. (ES) | 2022-04-06 | — | — | EP | disclosed |
| CN-107530436-B | Methods, compositions and systems for delivering therapeutic and diagnostic agents into cells | 菲泽尔克斯公司 | 2022-03-29 | — | — | CN | disclosed |
| US-11279954-B2 | Catecholamine enzyme fusions | OXFORD BIOMEDICA (UK) LTD. (GB) | 2022-03-22 | — | — | US | disclosed |
| WO-2022049154-A1 | HYDROGELS FOR CELL CULTURE | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-03-10 | — | — | WO | disclosed |
| EP-3963050-A1 | PREPARATION OF HUMAN ALLOGENEIC LIVER-DERIVED PROGENITOR CELLS | PROMETHERA THERAPEUTICS SA (BE) | 2022-03-09 | — | — | EP | disclosed |
| EP-3963049-A1 | PREPARATION OF HUMAN ALLOGENEIC LIVER-DERIVED PROGENITOR CELLS | PROMETHERA THERAPEUTICS SA (BE) | 2022-03-09 | — | — | EP | disclosed |
| US-11241398-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296912-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | OGFR, TNFSF11, FCER2 | XIAP 415/4885OPRD1 1049/4885NTSR1 83/4885 |
| US-20260007724-A1 | METHODS AND COMPOSITIONS FOR IMPROVING WOUND HEALING | MATR3, CHI3L2, SDC2 | XIAP 3893/4885OPRD1 2619/4885NTSR1 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.